Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0ZNAR)

• Drug Name: Belvarafenib Drug Info
• Synonyms: 1446113-23-0; UNII-31M3WLJ3KG; 31M3WLJ3KG; 4-Amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 4-amino-N-{1-[(3-chloro-2-fluorophenyl)amino]-6-methylisoquinolin-5-yl}thieno[3,2-d]pyrimidine-7-carboxamide; CHEMBL3977543; SCHEMBL15066408; BDBM185591; BCP31233; EX-A3061; s8853; HM95573; BS-15746; HY-109080; CS-0039257; Belvarafenib(GDC5573, HM95573, RG6185); US9156852, 116; 4-Amino-N-(1-(3-chloro-2-fluorophenylamino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 4-amino-N-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide; V1Y

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 89655386
  CAS Number: CAS 1446113-23-0
  TTD Drug ID: DM0ZNAR

Molecule-Related Drug Atlas

Drug(s) Targeting Proto-oncogene c-RAF (c-RAF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Semapimod	DMIJNLG	Autoimmune diabetes	5A10	Phase 2	[2]
BGB-3245	DM1X3L0	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
GDC-5573	DMJA27W	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proto-oncogene c-RAF (c-RAF)	TTB18GJ	RAF1_HUMAN	Inhibitor	[1]

References

• [1] Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
• [2] Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. J Immunol. 2005 Aug 15;175(4):2293-300.
• [3] Clinical pipeline report, company report or official report of BeiGene.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)